SkyView Investment Advisors LLC Takes $127,000 Position in Dynavax Technologies Co. (NASDAQ:DVAX)

SkyView Investment Advisors LLC acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,394 shares of the biopharmaceutical company’s stock, valued at approximately $127,000.

Several other large investors have also recently added to or reduced their stakes in DVAX. GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE increased its stake in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $45,000. Nisa Investment Advisors LLC increased its stake in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the period. Finally, Centiva Capital LP acquired a new position in shares of Dynavax Technologies during the third quarter valued at approximately $119,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Trading Up 0.6 %

Dynavax Technologies stock opened at $12.99 on Friday. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The firm’s 50 day moving average price is $11.98 and its two-hundred day moving average price is $11.47. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 99.93 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.